Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

60.36
-0.6900-1.13%
Pre-market: 60.35-0.0100-0.02%09:24 EDT
Volume:2.02M
Turnover:121.60M
Market Cap:10.03B
PE:-17.34
High:61.07
Open:61.07
Low:59.70
Close:61.05
52wk High:86.74
52wk Low:49.13
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.98
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:22.81
PE(LYR):-25.35

Loading ...

Ionis Pharmaceuticals price target raised to $69 from $66 at Goldman Sachs

TIPRANKS
·
Jul 30

Viking Therapeutics Reports Q2 Milder-than-expected Net Loss as Obesity Trials Advance

Reuters
·
Jul 30

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio

Benzinga Earnings
·
Jul 30

Ionis Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 30

Analysts Are Bullish on Top Healthcare Stocks: Option Care Health (OPCH), Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jul 29

Ionis Q2 Adjusted Operating Loss Narrows

Reuters
·
Jul 29

Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q2 Loss $0.69 a Share, vs. FactSet Est of $1.08 Loss

MT Newswires Live
·
Jul 29

Ionis Q2 FY26 Revenue Drops 40.71% to $268 Million; Operating Loss Widens to $102 Million

Reuters
·
Jul 29

Ionis Announces DR. Frank Bennett, Chief Scientific Officer, to Retire

THOMSON REUTERS
·
Jul 29

Ionis Pharmaceuticals Q2 Adj. EPS $(0.42) Beats $(1.07) Estimate, Sales $268.000M Beat $190.670M Estimate

Benzinga Earnings
·
Jul 29

Ionis Pharmaceuticals Q2 Adjusted Operating Expenses USD 325 Million

THOMSON REUTERS
·
Jul 29

Corrected-Ionis Pharmaceuticals Q2 Net Income USD -115 Million (Corrects Amount)

THOMSON REUTERS
·
Jul 29

Ionis Pharmaceuticals Inc: on Track to Achieve 2026 Financial Guidance

THOMSON REUTERS
·
Jul 29

Movement Alert|Ionis Pharmaceuticals Rises 5.39% in Regular Trading, Trading at $56.92

Market Focus
·
Jul 23

US High Growth Tech Stocks to Watch for Potential Expansion

Simply Wall St.
·
Jul 23

Earning Preview: Ionis Pharmaceuticals Q2 revenue is expected to decrease by 35.92%, and institutional views are cautious

Earnings Agent
·
Jul 23

Movement Alert|Ionis Pharmaceuticals Falls 5.16% in Regular Trading, Cardiovascular Pipeline Setback and Pre-Earnings Caution Weigh on Shares

Market Focus
·
Jul 22

Movement Alert|Ionis Pharmaceuticals Falls 6.35% in Pre-Market Trading, Bearish Sentiment Ahead of Earnings Compounded by Pipeline Setback

Market Focus
·
Jul 22

Ionis Pharmaceuticals is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 21

Ionis Pharmaceuticals Inc : Guggenheim Cuts Target Price to $89 from $106

THOMSON REUTERS
·
Jul 21